Engineered t cells take on tough leukemia and lymphoma
NCT ID NCT00466531
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a two-part treatment for people with relapsed or chemotherapy-resistant B-cell leukemia or lymphoma. First, patients receive a chemotherapy drug (cyclophosphamide) to help prepare the body. Then, they get an infusion of their own T cells that have been genetically modified in the lab to recognize and attack cancer cells carrying the CD19 protein. The study aims to check safety and how well this approach works in up to 50 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T cells (CAR T-cells) and cyclophosphamide chemotherapy
- What this could lead to
- If successful, this could point toward a new treatment option for patients with hard-to-treat B-cell cancers that have come back after standard therapy.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply to everyone. There are risks from the chemotherapy and the modified T cells, including severe immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's DNA guide better cancer care for kids?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?